Compare TLS & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLS | ALDX |
|---|---|---|
| Founded | 1969 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.9M | 317.7M |
| IPO Year | 2020 | 2014 |
| Metric | TLS | ALDX |
|---|---|---|
| Price | $4.30 | $4.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $7.75 | ★ $9.50 |
| AVG Volume (30 Days) | 715.4K | ★ 827.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $108,272,000.00 | N/A |
| Revenue This Year | $52.26 | N/A |
| Revenue Next Year | $19.65 | $123.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.83 | $1.18 |
| 52 Week High | $8.36 | $7.19 |
| Indicator | TLS | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 44.23 | 42.44 |
| Support Level | $3.82 | $4.74 |
| Resistance Level | $5.95 | $5.70 |
| Average True Range (ATR) | 0.26 | 0.33 |
| MACD | 0.07 | -0.07 |
| Stochastic Oscillator | 51.65 | 30.55 |
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.